Q1 Earnings Estimate for BPMC Issued By HC Wainwright

Blueprint Medicines Co. (NASDAQ:BPMC) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Blueprint Medicines in a research note issued on Thursday, October 31st. HC Wainwright analyst A. Fein forecasts that the biotechnology company will post earnings per share of ($0.60) for the quarter. HC Wainwright has a “Buy” rating and a $135.00 price target on the stock. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($3.65) per share. HC Wainwright also issued estimates for Blueprint Medicines’ Q2 2025 earnings at ($0.41) EPS and Q3 2025 earnings at ($0.19) EPS.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The firm had revenue of $128.20 million during the quarter, compared to analyst estimates of $127.56 million. During the same quarter last year, the business earned ($2.20) EPS. The business’s revenue was up 126.5% on a year-over-year basis.

Other equities analysts have also recently issued research reports about the company. UBS Group assumed coverage on Blueprint Medicines in a report on Thursday, October 24th. They set a “neutral” rating and a $88.00 price objective for the company. Morgan Stanley upped their price target on shares of Blueprint Medicines from $110.00 to $115.00 and gave the stock an “equal weight” rating in a report on Friday, July 12th. Guggenheim lifted their price objective on shares of Blueprint Medicines from $130.00 to $138.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Needham & Company LLC restated a “buy” rating and issued a $133.00 target price on shares of Blueprint Medicines in a research note on Wednesday, October 30th. Finally, StockNews.com downgraded shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $120.39.

Blueprint Medicines Trading Up 6.2 %

BPMC opened at $97.55 on Monday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32. The stock’s 50 day moving average price is $88.72 and its 200-day moving average price is $98.57. Blueprint Medicines has a one year low of $56.74 and a one year high of $121.90. The stock has a market cap of $6.20 billion, a price-to-earnings ratio of -46.23 and a beta of 0.59.

Insider Transactions at Blueprint Medicines

In other Blueprint Medicines news, insider Fouad Namouni sold 3,633 shares of the stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total value of $324,499.56. Following the completion of the sale, the insider now directly owns 69,070 shares in the company, valued at approximately $6,169,332.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 4.21% of the company’s stock.

Institutional Investors Weigh In On Blueprint Medicines

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in Blueprint Medicines by 3.2% during the 1st quarter. Vanguard Group Inc. now owns 6,309,977 shares of the biotechnology company’s stock worth $598,564,000 after acquiring an additional 195,007 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Blueprint Medicines by 15.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,250,823 shares of the biotechnology company’s stock worth $592,954,000 after purchasing an additional 821,868 shares during the period. American Century Companies Inc. boosted its position in Blueprint Medicines by 4.2% in the second quarter. American Century Companies Inc. now owns 802,733 shares of the biotechnology company’s stock valued at $86,519,000 after buying an additional 32,600 shares during the last quarter. Millennium Management LLC increased its holdings in Blueprint Medicines by 540.0% in the 2nd quarter. Millennium Management LLC now owns 627,626 shares of the biotechnology company’s stock worth $67,646,000 after buying an additional 529,566 shares during the period. Finally, Hood River Capital Management LLC raised its position in Blueprint Medicines by 7.0% during the 2nd quarter. Hood River Capital Management LLC now owns 502,820 shares of the biotechnology company’s stock worth $54,194,000 after buying an additional 32,694 shares during the last quarter.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.